title: The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure.
abstract: OBJECTIVE
  To evaluate the effect of a latanoprost/timolol fixed combination (LTFC) versus a latanoprost and timolol gel-forming solution unfixed combination (LTuFC) on daytime intraocular pressure (IOP) levels and fluctuations.
  
  
  METHODS
  This was an 8-week, randomized, parallel-group study. Ninety eyes of 90 patients diagnosed with primary open-angle glaucoma or ocular hypertension that were insufficiently controlled with latanoprost monotherapy were enrolled. Randomized patients received either a single evening dose of LTFC or unfixed combination of latanoprost administered once daily in the evening and timolol gel-forming solution administered once daily in the morning without a washout period. IOP measurements were taken at 8 AM, 11 AM, 2 PM, and 5 PM. The mean IOP, daytime IOP measurements, and fluctuation in IOP were assessed at weeks 4 and 8.
  
  
  RESULTS
  The mean IOP reduction from baseline to each visit was significant in both groups (P<0.01). There was a significant difference in the mean IOP between groups at week 4 (P=0.0021). At week 8, the mean IOP reduction was 3.2 ± 2.1 and 5.7 ± 3.2 mm Hg in LTFC and LTuFC groups, respectively, and the difference was significant (P=0.001). A decrease in the daytime IOP fluctuation was observed in both groups over time, but the decrease in each group was not significant. At week 8, the mean IOP measurements at 8 AM, 11 AM, 2 PM, and 5 PM in LTuFC group were significantly lower than in the LTFC group (P=0.024, 0.0001, 0.0008, and 0.0011, respectively).
  
  
  CONCLUSIONS
  The concomitant use of latanoprost and timolol gel-forming solution leads to a larger additional IOP reduction and lower daytime IOP levels as compared with the fixed combination.
authors.affiliation: Department of Ophthalmology, Ünye State Hospital, Ordu, Turkey.
authors.forename: Erhan
authors.initials: E
authors.lastname: Özyol
authors.forename: Pelin
authors.initials: P
authors.lastname: Özyol
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005782:Gels; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*; D014065:Tonometry, Ocular; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D005782:Gels; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol